Adjuvant Immunotherapy for Resectable NSCLC

Explore the benefits and considerations of adjuvant immunotherapy in the treatment of resectable non-small cell lung cancer (NSCLC). Review the latest clinical trials, including IMpower 010 and Checkmate 816, and learn about the potential role of neoadjuvant therapy.

11 views • 28 slides